Clinic Roundup
Bavarian Nordic AS, of Kvistgard, Denmark, reached a special protocol assessment agreement with the FDA for a Phase III registration study of Prostvac, an off-the-shelf therapeutic vaccine being developed under a cooperative research and development agreement with the National Cancer Institute, in patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.